↓ Skip to main content

Serial pseudoprogression of metastatic malignant melanoma in a patient treated with nivolumab: a case report

Overview of attention for article published in BMC Cancer, November 2017
Altmetric Badge

Mentioned by

twitter
1 X user

Citations

dimensions_citation
22 Dimensions

Readers on

mendeley
39 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Serial pseudoprogression of metastatic malignant melanoma in a patient treated with nivolumab: a case report
Published in
BMC Cancer, November 2017
DOI 10.1186/s12885-017-3785-4
Pubmed ID
Authors

Yukinori Ozaki, Junichi Shindoh, Yuji Miura, Hiromichi Nakajima, Ryosuke Oki, Miyuki Uchiyama, Jun Masuda, Keiichi Kinowaki, Chihiro Kondoh, Yuko Tanabe, Tsuyoshi Tanaka, Shusuke Haruta, Masaki Ueno, Shigehisa Kitano, Takeshi Fujii, Harushi Udagawa, Toshimi Takano

Abstract

Pseudoprogression refers to a specific pattern of response sometimes observed in malignant melanoma patients receiving treatment with immune-checkpoint inhibitors. Although cases with pseudoprogression documented once have been reported previously, there have been no case reports yet of pseudoprogression events documented twice during treatment. A 55-year-old man underwent surgery for locally advanced esophageal malignant melanoma and received postoperative adjuvant interferon therapy. However, he presented with multiple liver and bone metastases at 6 months after the surgery, and was initiated on treatment with nivolumab 2 mg/kg every 3 weeks as the first-line treatment for recurrent disease. Follow-up computed tomography revealed that the liver metastases initially increased transiently in size, but eventually regressed. However, while the liver metastases continued to shrink, a new peritoneal nodule emerged, that also subsequently shrinked during the course of treatment with nivolumab. With only grade 1 pruritus, the patient continues to be on nivolumab treatment at 15 months after the induction therapy, with no progression observed after the second episode of pseudoprogression in the liver and peritoneal nodule. We present the case of a patient with metastatic malignant melanoma who showed the unique response pattern of serial pseudoprogression during treatment with nivolumab. This case serves to highlight the fact that development of a new lesion may not always signify failure of disease control during treatment with nivolumab.

X Demographics

X Demographics

The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 39 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 39 100%

Demographic breakdown

Readers by professional status Count As %
Researcher 8 21%
Student > Doctoral Student 5 13%
Other 3 8%
Student > Bachelor 3 8%
Student > Ph. D. Student 3 8%
Other 6 15%
Unknown 11 28%
Readers by discipline Count As %
Medicine and Dentistry 23 59%
Immunology and Microbiology 1 3%
Biochemistry, Genetics and Molecular Biology 1 3%
Neuroscience 1 3%
Engineering 1 3%
Other 0 0%
Unknown 12 31%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 26 November 2017.
All research outputs
#20,452,930
of 23,008,860 outputs
Outputs from BMC Cancer
#6,529
of 8,359 outputs
Outputs of similar age
#372,570
of 437,733 outputs
Outputs of similar age from BMC Cancer
#119
of 155 outputs
Altmetric has tracked 23,008,860 research outputs across all sources so far. This one is in the 1st percentile – i.e., 1% of other outputs scored the same or lower than it.
So far Altmetric has tracked 8,359 research outputs from this source. They receive a mean Attention Score of 4.3. This one is in the 1st percentile – i.e., 1% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 437,733 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 155 others from the same source and published within six weeks on either side of this one. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.